BridgeMD
New treatment option for Ischemic Stroke
Official title Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial
ClinicalTrials.gov ID: NCT06737549
What this study is testing
What is Nerver growth factor (NGF) injection?
Nerver growth factor (NGF) injection is an investigational medicine, given as an injection into a muscle, being studied as a potential treatment for ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Ischemic stroke is a common clinical disease, often accompanied by dysphagia. At present, clinical treatment for patients with dysphagia after ischemic stroke is limited.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients with first-ever ischemic stroke confirmed by Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI);
- Onset time ranged from 15 days to 180 days;
- Aged 18 to 80 years old, male or female;
- Dysphagia confirmed by a videofluoroscopic swallowing study (VFSS);
- Patients who are able to accept and comply with acupuncture, electroacupuncture treatment, gluteal intramuscular injection, and have good compliance;
You likely can't join if
- Patients with dysphagia before ischemic stroke onset or dysphagia not caused by ischemic stroke;
- Patients with severe cognitive impairment;
- Patients with severe cardiac, hepatic, and renal dysfunction, as well as severe coagulation abnormalities;
- Patients with other abnormal test results who are deemed unsuitable to participate in this study by the investigator.
- Multiple occurrences of stroke, or a history of craniocerebral surgery, or cerebral infarction caused by trauma or brain tumors.
- Patients with severe neurological deficits prior to ischemic stroke, such as visual and auditory impairments, aphasia, agnosia, severe hemiplegia...
See the full eligibility criteria
- Patients with first-ever ischemic stroke confirmed by Computed Tomography (CT) and/or Magnetic Resonance Imaging (MRI);
- Onset time ranged from 15 days to 180 days;
- Aged 18 to 80 years old, male or female;
- Dysphagia confirmed by a videofluoroscopic swallowing study (VFSS);
- Patients who are able to accept and comply with acupuncture, electroacupuncture treatment, gluteal intramuscular injection, and have good compliance;
- Have provided signed consent and exhibit willingness to participate in the trial.
- Women who are lactating, pregnant or intending to get pregnant;
- Patients with dysphagia before ischemic stroke onset or dysphagia not caused by ischemic stroke;
- Patients with severe cognitive impairment;
- Patients with severe cardiac, hepatic, and renal dysfunction, as well as severe coagulation abnormalities;
- Patients with other abnormal test results who are deemed unsuitable to participate in this study by the investigator.
- Multiple occurrences of stroke, or a history of craniocerebral surgery, or cerebral infarction caused by trauma or brain tumors.
- Patients with severe neurological deficits prior to ischemic stroke, such as visual and auditory impairments, aphasia, agnosia, severe hemiplegia, and other conditions.
- Women who are lactating, pregnant or intending to get pregnant;
- Patients with a history of needle fainting or with skin infections at the acupuncture site.
- Cardiac pacemaker carrier;
- Patients allergic to NGF;
- The inability to undergo VFSS;
- Patients with a medication history that may alter cortical excitability within the past 2 months.
- Patients who are currently participating in other clinical trials or have participated in clinical trials that ended within the last 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.